Table 1 Clinical, laboratory and procedural characteristics of the overall study population, and of patients with normal (< 6%) and elevated (≥ 6%) hemoglobin A1c (HbA1c)
Characteristics | Overall (n = 315) | HbA1c < 6% (n = 156)* | HbA1c ≥ 6% (n = 145)* | p |
|---|---|---|---|---|
Demographics | ||||
 Age, years | 66 (58–75) | 65 (57–74) | 66 (58–75) | 0.4 |
 Male sex | 205 (65.1) | 103 (66) | 95 (65.5) | 0.9 |
 BMI, kg/m2 | 26.8 (24.2–29.7) | 26.2 (23.4–28.7) | 27.3 (25.1–29.7) | 0.007 |
Medical history | ||||
 Hypertension | 283 (89.8) | 135 (86.5) | 134 (92.4) | 0.1 |
 Hypercholesterolemia | 293 (93) | 144 (92.3) | 136 (93) | 0.6 |
 Diabetes mellitus | 102 (32.4) | 11 (7.1) | 85 (58.6) | < 0.001 |
 Active smoking | 132 (41.9) | 76 (48.7) | 53 (36.6) | 0.03 |
Laboratory data | ||||
 HbA1c, %* | 5.9 (5.6–6.5) | 5.6 (5.4–5.8) | 6.5 (6.1–7.2) | <0.001 |
 Hematocrit, % | 38.9 (36–42) | 39.6 (36.4–42.6) | 38.7 (35.4–41.4) | 0.1 |
 White blood cell count, G/l | 8.4 (6.9–10.4) | 8.2 (6.8–10.3) | 8.7 (7–10.6) | 0.3 |
 Platelet count, G/l | 208 (176–251) | 207 (173–249) | 210 (177–259) | 0.6 |
 Serum creatinine, mg/dl | 1 (0.9–1.2) | 1 (0.9–1.1) | 1 (0.9–1.3) | 0.2 |
 High-sensitivity CRP, mg/dl | 0.8 (0.3–1.8) | 0.9 (0.3–2.1) | 0.8 (0.3–1.7) | 0.4 |
Procedure | ||||
 Stent implantation | 315 (100) | 156 (100) | 145 (100) | 1 |
 Number of stents/patient | 1 (1–2) | 1 (1–2) | 1 (1–2) | 0.3 |
Medication pre-intervention | ||||
 Clopidogrel | 315 (100) | 156 (100) | 145 (100) | 1 |
 Aspirin | 315 (100) | 156 (100) | 145 (100) | 1 |
 Statins | 300 (95.2) | 149 (95.5) | 139 (95.9) | 0.9 |
 ACE inhibitors/ARB | 272 (86.3) | 135 (86.5) | 124 (85.5) | 0.8 |
 Beta blockers | 216 (68.6) | 104 (66.7) | 105 (72.4) | 0.3 |
 Proton pump inhibitors | 165 (52.4) | 75 (48.1) | 81 (55.9) | 0.2 |
 Antidiabetic medication | 96 (30.5) | 11 (7.1) | 79 (54.5) | < 0.001 |
 Oral antidiabetic medication | 77 (24.4) | 8 (5.1) | 67 (46.2) | < 0.001 |
 Insulin | 30 (9.5) | 3 (1.9) | 23 (15.9) | < 0.001 |